Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selection
After watching this activity, participants should be better able to:
- Discuss the rationale for using PARP inhibitors in the first-line maintenance treatment of advanced ovarian cancer
- Identify patients who may benefit from a PARP inhibitor in the first-line maintenance setting
- Describe the key factors that can inform selection of the most appropriate PARP inhibitor for each patient
In this activity, gynaecologic oncology specialists Prof. Nicoletta Colombo and Dr Natalia R Gómez-Hidalgo discuss three key topics relating to PARP inhibitors in the first-line maintenance setting for advanced ovarian cancer – rationale for use, which patients may particularly benefit, and key factors informing PARP inhibitor selection. Discussion on these themes is based on questions posed by healthcare professionals involved in the care of patients with ovarian cancer.
To obtain the CE credit(s) from this activity, please complete this post-activity test.Claim Credit
You may also be interested in...
Maximizing the potential of PARP inhibitors as first-line maintenance therapy in ovarian cancer: Improving patient identification and treatment selectionThis activity is CE/CME accredited
Domenica Lorusso, ESMO 2021: Relacorilant in Combination with Nab-paclitaxel for Patients with Recurrent Platinum-resistant Ovarian Cancer
Linda Mileshkin, ESMO 2019 – Phase III OUTBACK trial in cervical cancer
Foreword – European Oncology, 2008;4(1):10
Is There an Optimal First-line Regimen for Advanced Ovarian Cancer? Variations on a Theme
PARP inhibitors as first-line maintenance therapy in ovarian cancer: Using data from SGO 2022 to inform clinical best practiceThis activity is CE/CME accredited
Journal articles and more to your inbox
Get the latest clinical insights from touchONCOLOGYSign me up!